long intergenic non-protein coding RNA 661Genealiases: []
Q-omics provides the consensus-scored LINC00661 profile across patient tissues and cancer cell-line models. LINC00661 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, LINC00661 is differentially expressed in 5, with the highest sampling consensus in PAAD. Additionally, LINC00661 RNA expression shows 6,421 significant pathway-activity associations, with the highest sampling consensus in UCEC. Together, these results highlight HNSC, PAAD, and UCEC as cancer lineages where LINC00661 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC00661 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC00661 survival associations across molecular data types. LINC00661 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC00661 RNA expression–survival associations across cancer types. High LINC00661 expression shows unfavorable associations in KIRC, ACC, DLBC, LIHC and READ, but favorable associations in HNSC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for LINC00661 RNA expression.
This table summarizes LINC00661 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for LINC00661. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC00661 shows lower tumor expression in PAAD, THCA, KICH and LUAD and higher tumor expression in LUSC. The PAAD box plot shows higher LINC00661 RNA expression in normal versus tumor tissue (log2 FC = −1.060, t-test p = .048).
This table shows molecular features associated with LINC00661 in patient tissues and cancer cell lines. In patient samples, LINC00661 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set. In cancer cell lines, LINC00661 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC.
